Pre-approval Access to IMPs

Ablynx Policy on Pre-Approval Access to Investigational Medicinal Products (IMP)

Ablynx’s mission is to create new medicines which will make a real difference to the lives of patients. As part of that mission, Ablynx is firmly committed to advancing, as rapidly as possible, the development of the most promising Nanobodies®, and making them available to patients as soon as Regulatory Agencies consider that safety and efficacy have been sufficiently established.

Currently, Ablynx does not provide access to investigational medicinal products outside of clinical trials.

Any communication related to pre-approval access to investigational medicinal products should be sent to our Medical Department (pre-approval@ablynx.com). We will acknowledge receipt of all communications in 24h.